Insider Transactions in Q2 2024 at Apellis Pharmaceuticals, Inc. (APLS)
Insider Transaction List (Q2 2024)
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 28
2024
|
A. Sinclair Dunlop Director |
BUY
Exercise of conversion of derivative security
|
Direct |
900
+0.67%
|
$11,700
$13.19 P/Share
|
Jun 21
2024
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Indirect |
37,000
-10.76%
|
$1,443,000
$39.43 P/Share
|
May 20
2024
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,500
+2.1%
|
$73,500
$3.76 P/Share
|
May 08
2024
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
78,907
-2.23%
|
$3,393,001
$43.01 P/Share
|
May 08
2024
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
78,907
+6.19%
|
$315,628
$4.31 P/Share
|
Apr 18
2024
|
Timothy Eugene Sullivan Chief Financial Officer |
BUY
Bona fide gift
|
Indirect |
14,164
+16.75%
|
-
|
Apr 18
2024
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Bona fide gift
|
Direct |
14,164
-15.18%
|
-
|
Apr 12
2024
|
A. Sinclair Dunlop Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+1.11%
|
$19,500
$13.19 P/Share
|
Apr 08
2024
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
69,107
-2.93%
|
$3,731,778
$54.52 P/Share
|
Apr 08
2024
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
69,107
+5.51%
|
$207,321
$3.76 P/Share
|
Apr 01
2024
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,000
-4.11%
|
$232,000
$58.66 P/Share
|
Apr 01
2024
|
Timothy Eugene Sullivan Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+3.95%
|
$40,000
$10.03 P/Share
|